期刊文献+

白藜芦醇对兔动脉粥样硬化基质金属蛋白酶表达的影响 被引量:2

Effect of resveratrol on expression of matrix metalloproteinase in rabbits with athrosclerosis
原文传递
导出
摘要 目的探讨白藜芦醇对实验性动脉粥样硬化兔基质金属蛋白酶(MMP)表达的影响。方法选择新西兰纯种雄性大白兔50只随机分为三组,正常对照组10只,模型组20只,白藜芦醇组20只。采用液氮冻伤术建立动脉硬化模型,造模2个月后采用液氮冻伤术激发动脉硬化斑块破裂,模后2个月及激发试验后48h后分别对三组动物测定MMP-1、9的浓度。结果模型组造模后2个月MMP-1、9的浓度分别为(50.74±5.49)ng/ml和(337.69±8.98)ng/ml,同期白藜芦醇组MMP-1、9的浓度分别为(41.33±9.58)ng/ml和(309.83±10.59)ng/ml(P<0.01),激发试验48h后模型组MMP-1、9的浓度分别为(100.35±6.58)ng/ml和(869.56±12.37)ng/ml,同期白藜芦醇组MMP-1、9的浓度分别为(61.68±11.69)ng/ml和(411.24±15.74)ng/ml(P<0.01)。结论白藜芦醇能够降低MMP-1、9的浓度,从而预防和延缓动脉硬化的发生。 Objective To study the effect of resveratrol on expression of matrix metalloproteinase (MMP) in rabbits with experimental atherosclerosis. Methods Fifty New Zealand healthy rabbits were randomly divided into normal control group(n=10), atherosclerosis model group(n=20), and resveratrol group(n=20).Two months after an atherosclerosis model was established using liquid nitrogen, cold injury was induced to provoke rupture of atherosclerosis plaque. Levels of MMP-1 and 9 were measured 2 months after model establishment and 48 hours after provocation test, respectively. Results The levels of MMP-1 and 9 were 50.74±5.49ng/ml and 337.69±8.98ng/ml in model group and 41.33±9.58ng/ml and 309.83±10.59ng/ml in resveratrol group, respectively, 2 months after model establishment(P0.01), while they were 100.35±6.58ng/ml and 869.56±12.37ng/ml in model group and 61.68±11.69ng/ml and 411.24±15.74ng/ml in resveratrol group, respectively, 48 hours after provocation test(P0.01). Conclusion Resveratrol can prevent and delay the occurrence of atherosclerosis by reducing the level of MMP-1 and MMP-9.
机构地区 解放军第
出处 《军医进修学院学报》 CAS 2010年第4期356-357,366,共3页 Academic Journal of Pla Postgraduate Medical School
基金 全军"十一.五"医药卫生科研基金项目(06G145)~~
关键词 动脉硬化 白藜芦醇 基质金属蛋白酶 Atherosclerosis Resveratrol Matrix Metalloproteinases Rabbits
  • 相关文献

参考文献11

  • 1任冰稳.动脉粥样硬化与基质金属蛋白酶[J].中国循环杂志,2002,17(1):73-74. 被引量:33
  • 2Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safty of simvastatin 80mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U. S. Study Group [ J ] . Am J Cardiol, 1998, 82 : 311-316.
  • 3董德刚,郭恩绵,张瑶,鲁艳明,张淑兰.白藜芦醇对宫颈癌HeLa细胞基质金属蛋白酶及其组织抑制剂的影响[J].中华肿瘤防治杂志,2007,14(7):489-493. 被引量:12
  • 4余海波,潘承恩,吴武军,赵四海,张慧峰.白藜芦醇对肝癌细胞基质金属蛋白酶-9表达的影响[J].中西医结合学报,2008,6(3):270-273. 被引量:9
  • 5葛恒,张俊峰,郭炳诗,何奔,王彬尧,王长谦.白藜芦醇抑制巨噬细胞细胞外基质金属蛋白酶诱导物的表达[J].药学学报,2006,41(7):625-630. 被引量:11
  • 6Lee RT, Schoen FJ, Loree HM, et al. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture [ J ] . Arteriosd Thromb Vasc Biol, 1996, 16 : 1070-1073.
  • 7Funayama H, Ishikawa SE, Kuho N, et al. Increases in interleukin-6 and matrix metalloprotdnase-9 in the infarct-related coronary artery of acute myocardial infarction [ J ] . Circ J, 2004, 68 : 451-454.
  • 8Eekart RE, Uyehara CF, Shry EA, et al. Matrix metallo proteinases in patients with myocardial infarction and percutaneous revaseularization [ J ] . J Intery Cardiol, 2004, 17 : 27-31.
  • 9Blankenberg S, RuPPreeht H J, Poirier O, et al. AiheroGene Investigators. Plasma Concentrations and genetic variation of matrix metalloproteinase 9 and Prognosis of Patients with cardiovase- ular disease [ J ] . Circulation, 2003, 107 : 1579-1585.
  • 10Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury [J ] . Circ Res, 2002, 91 : 845-851.

二级参考文献24

共引文献61

同被引文献57

  • 1赵晓晖,周媛,沈健,夏卫英,王连文,白青科.基质金属蛋白酶-9与脑梗死颈动脉粥样斑块相关性及阿托伐他汀干预后的变化[J].脑与神经疾病杂志,2010,18(5):321-324. 被引量:7
  • 2黄烨,陈登峰,袁璐,刘艳,刘华,张柳,孔珺,王虹.乳腺肿块微血管密度与血氧近红外光参数的实验研究[J].肿瘤防治研究,2007,34(1):51-53. 被引量:35
  • 3李华,高建华,颜玲,鲁峰,朱茗.成人外周血单个核细胞体外培养过程中分化为早及晚期内皮祖细胞生物学表征[J].中国组织工程研究与临床康复,2007,11(24):4682-4685. 被引量:3
  • 4Back M, Ketelhuth D F, Agewall S. Matrix Metalbproteinases in Atherothro- mbosis [J]. Prog Cardiovasc Dis, 2010, 52(5) :410-428.
  • 5Cdqui MH, Fronek A, Barrett-Connor E,et al.The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510-515.
  • 6Newman AB, Sutton-Tyrrell K, Vogt MT, et aLMorbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index.JAMA. 1993;270(4):487-489.
  • 7Klinkert P, Schepers A, Burger DH,et al.Vein versus polytetrafluomethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trlal.J Vasc Surg. 2003;37(1):149-155.
  • 8van Weel V, van Tongeren RB, van Hinsbergh VW,et al.Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation.Ann Vasc Surg. 2008;22(4):582-597.
  • 9Kalka C, Baumgartner I.Gene and stem cell therapy in peripheral artedal occlusive disease.Vasc Med. 2008;13(2): 157-172.
  • 10Tateishi-Yuyama E, Matsubara H, Murohara T, et at.Therapeutic angiogenesis for patients with limb ischaemia by autoicgous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.Lancet. 2002;360(9331):427-435.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部